Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-426
2016-000588-17Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- Jul 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) and kidney cancer comparing Pembrolizumab + axitinib with Sunitinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on 2016-000588-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000588-17.